HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Home About Us Dr. Kenichiro Hasumi

Thursday29 June 2017

Dr. Kenichiro Hasumi

ProfileBiographyPublication

Profile of Dr. Kenichiro HASUMI, M.D.

Dr. Kenichiro Hasumi is a physician who specializes in cancer immunotherapy as well as terminal and palliative care. He is a visionary researcher focused on the development of cancer vaccines and improved clinical treatments to achieve better patient outcomes with a higher quality of life.

He has been involved in cancer immunotherapy research for more than 40 years. His father, Dr. Kiichiro Hasumi, was a renowned doctor and scientist who spent his lifetime researching cancer vaccine. Dr. Kiichiro was among the first to discover that some viruses cause cancer.

It is well accepted today that many cancers are caused by viruses, such as cervical cancer with by human papilloma virus and liver cancer by hepatitis B and C viruses. Dr Kiichiro developed a cancer vaccine (“Hasumi Vaccine”) and established the Shukokai Clinic, Japan to provide treatment to patients.

Dr. Kenichiro Hasumi succeeded his father’s position in Shukokai Clinic in 1988 and he advanced several collaborative research projects between Shukokai and foreign medical schools to study the biological activity of the Hasumi Vaccine. Over 100,000 cancer patients have used the Hasumi vaccine during the past fifty years in more than twenty countries, without the occurrence of any severe side effects.

Shukokai Clinic
Shukokai Clinic, Japan
Shukokai Clinic
Shukokai Clinic, Japan
Jilin Provincial Cancer Hospital
Jilin Provincial Cancer Hospital, China

Dr. Hasumi is the Chairman of Shukokai Clinic, Hijirigaoka Hospital, Hijiri-no-Sato Elderly Health Care Facility, and The Electro-Chemical and Cancer Institute; all these institutions are located in Tokyo, Japan.

In 1997, Dr. Kenichiro Hasumi was appointed visiting professor at Thomas Jefferson University where he established the Hasumi Laboratory for carrying out research and development of immunotherapy.

In 1998, Dr. Hasumi started joint research with the Jilin Provincial Cancer Hospital, China; and he was appointed Chairman Emeritus of this hospital.

Dr. Hasumi at the inauguration of the Hasumi International Research Foundation at Jefferson University as founder, Chairman and CEO of the foundation.

With him are Paul C. Brucker, MD, University President (left) and Joseph Gonnella, Dean, Jefferson Medical College and Senior Academic Advisor for the Foundation (right). (1999)

Dr. Hasumi’s deep-seated commitment and dedication to research and championing new treatments and cure for cancer leaves no doubt when he was appointed as the Chairman of Hasumi International Research Foundation in the United States in 1999 and have since spearheaded many researches in tumour immunology and genetics.

In the year 2000, Dr. Hasumi shifted his research to the therapeutic vaccine based on patient derived immature dendritic cells. He established the current cancer treatment protocol known as “HITV therapy” which has been found to be highly effective in treating late stage cancer patients. 

In 2001 Dr. Hasumi in joint research with Thomas Jefferson University, developed the Hasumi DC & AT Vaccine and commenced clinical applications with the vaccine. 

In 2005, He was the primary organizer and founder for the World Immuno-Society for Health (WISH, Switzerland) a non-profit organization helping physicians, patients and their families become more aware and understanding of cancer treatment and care through networking. 

In 2006, he founded the Hasumi International Research Foundation in Bulgaria. And by 2008, he started HITV therapy at ICVS Tokyo Clinic.

Dr. Pastel from the USA handed the prize for best cancer researcher of the Medical school of Thomas Jefferson University to Dr. Kenichiro Hasumi. (2007)
Dr. Pastel from the USA handed the prize for best cancer researcher of the Medical school of Thomas Jefferson University to Dr. Kenichiro Hasumi. (2007)
First International Conference of the Hasumi International Research Foundation-USA, Tokyo, December 2006
First International Conference of the Hasumi International Research Foundation-USA, Tokyo, December 2006
The inauguration of ICVS Incorporated – Tokyo Clinic & Research Institute on October 2, 2007
The inauguration of ICVS Incorporated – Tokyo Clinic & Research Institute on October 2, 2007
Dr. Kenichiro Hasumi was awarded with the Medal “For Merits to the Bulgarian Academy of Sciences” during the "Oncoprogress-Oncovaccines 2010” at the Fourth Annual Meeting of Hasumi International Research Foundation, Bulgaria.
Dr. Kenichiro Hasumi was awarded with the Medal “For Merits to the Bulgarian Academy of Sciences” during the "Oncoprogress-Oncovaccines 2010” at the Fourth Annual Meeting of Hasumi International Research Foundation, Bulgaria
Dr. Hasumi, pictured here with Emeritus Prof Dr. Cheong Soon Keng, Dean Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman (Malaysia)
Dr. Hasumi, pictured here with Emeritus Prof Dr. Cheong Soon Keng, Dean Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman (Malaysia)
The Ambassador of Bulgaria in Japan, academician Blagovest Sendov, delivered a speech during the ICVS inauguration event
The Ambassador of Bulgaria in Japan, academician Blagovest Sendov, delivered a speech during the ICVS inauguration event.

In 2009, Dr. Hasumi started an FDA clinical trial of HITV therapy at the University of Maryland, USA ( Project Name: “Autologous Dendritic Cells Derived From Peripheral Blood Mononuclear Cells Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4 (CellGenix); Administered Intratumoral” ).

The fruits of his labour is seen when Dr. Hasumi successfully patented the Dendritic Cell Tumor Injection Therapy in Singapore (2009) and in the United States. The same therapy is currently in process for patent application in the United States.

Since 2001, the Hasumi International Research Foundation has sponsored seven international Cancer Vaccine Symposiums around the world, which were attended by well renowned scientists in the field of anti-cancer vaccines.

Over the span of 28 years, Dr. Hasumi has more than 35 international publications to date under his belt and is still involved in more research projects. His perseverance to find a cure for cancer is an inspiration to many and HITV Lab is proud to be associated with Dr. Kenichiro Hasumi on his journey to finding a cure for cancer.

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks